AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceNamed GroupsHealth Care
Multiple MyelomaTransplantation, AutologousHematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationMelphalanTransplantation ConditioningLiver TransplantationStem Cell TransplantationThalidomideKidney TransplantationMyeloma ProteinsBoronic AcidsHematopoietic Stem Cell MobilizationPyrazinesTreatment OutcomePeripheral Blood Stem Cell TransplantationCombined Modality TherapyGraft SurvivalAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyLymphoma, Non-HodgkinRecurrenceCell TransplantationPlasma CellsAntigens, CD34Bone Marrow PurgingRemission InductionCyclophosphamideCarmustineHeart TransplantationBone MarrowDexamethasoneLeukapheresisLung TransplantationWhole-Body IrradiationGranulocyte Colony-Stimulating FactorParaproteinemiasDisease-Free SurvivalGraft vs Host DiseaseSurvival AnalysisHematopoietic Stem CellsRetrospective StudiesSurvival RateHematologic NeoplasmsBusulfanEtoposideHodgkin DiseaseTime FactorsOrgan TransplantationAntineoplastic AgentsVincristinePrognosisImmunosuppressive AgentsBlood Transfusion, AutologousLeukemia, Plasma CellMonoclonal Gammopathy of Undetermined SignificanceMyeloablative AgonistsFollow-Up StudiesBone Marrow CellsGraft vs Tumor EffectPrednisoneGraft RejectionPlasmacytomaCytarabineAntineoplastic Agents, AlkylatingTissue DonorsPancreas TransplantationIslets of Langerhans TransplantationTransplantation ImmunologyTransplantationLymphomaBlood Component RemovalDoxorubicinTransplantation ChimeraSyndecan-1LeukemiaNeoplasm, ResidualKanamycin KinaseFlow CytometryAntibodies, MonoclonalTransplantation, IsogeneicCells, CulturedFeasibility StudiesCell SeparationHematopoiesisBlood Cell CountDisease ProgressionGenetic TherapyCell Line, TumorAntigens, CDMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLiving DonorsTransplantation, HeterotopicColony-Forming Units AssayCord Blood Stem Cell TransplantationImmunomagnetic SeparationIdarubicinProspective Studies
LymphomaASCTAllogeneic hemaHigh dose chemotherapyNewly diagnosed multipleMelphalanMarrow transplantationDexamethasoneChemotherapyProgenitorCases of multiple myelomaCancersPeople living withStem cell transTherapiesPeripheral blood stemRisk of multiple myelomaCombination with filgrastimActive multiple myelomaPlasma cell myEngraftmentHematologic malignanciesMobilize2023OncologyFilgrastimBone Marrow TraTreatmentRelapseSurvivalPrognosisSolid tumorsComplicationsDiagnosisLeukemiaHSCTMonoclonalTherapeuticTransplantsMaintenance therapyTherapyLentiviral vectorBortezomibCRAB
Lymphoma11
ASCT7
Allogeneic hema2
  • The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score is a useful tool to assess the risk for nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation. (austral.edu.ar)
  • Participant has previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or B-cell maturation antigen targeted therapy. (who.int)
High dose chemotherapy1
  • The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
Newly diagnosed multiple4
  • We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. (scielo.br)
  • Review of 1027 patients with newly diagnosed multiple myeloma. (scielo.br)
  • Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm. (cancernetwork.com)
  • While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. (biomedcentral.com)
Melphalan2
Marrow transplantation3
Dexamethasone5
Chemotherapy3
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • Although treatment strategies changed from traditional chemotherapy and autologous hematopoietic stem cell transplantation to novel targeted drug therapy, the outcome was not improved ( 2 ). (spandidos-publications.com)
  • Chemotherapy, either at conventional levels or in the higher-dosed myeloablative protocols used in conditioning regimens (with or without total body radiation in preparation for hematopoietic cell transplantation [HCT]), often results in erythema, edema, atrophy, and ulceration of the oral mucosa, a condition generally referred to as oral mucositis. (medscape.com)
Progenitor4
  • Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
  • Here, we demonstrate that ex vivo treatment with an oncolytic poxvirus called myxoma virus results in specific elimination of human myeloma cells by inducing rapid cellular apoptosis while fully sparing normal hematopoietic stem and progenitor cells. (elsevierpure.com)
  • The specificity of this elimination is based on strong binding of the virus to myeloma cells coupled with an inability of the virus to bind or infect CD34 + hematopoietic stem and progenitor cells. (elsevierpure.com)
  • Early fate decisions in hematopoietic stem and progenitor cells. (lu.se)
Cases of multiple myeloma1
Cancers2
People living with1
  • In 2020, there were an estimated 170,405 people living with myeloma in the U.S. It is difficult to judge mortality statistics because treatments for the disease are advancing rapidly. (wikipedia.org)
Stem cell trans2
Therapies5
  • While many of the Cancer Institute's patients are able to receive the most advanced therapies for their diagnosis close to home, people who needed hematopoietic cell transplant or cellular immunotherapy have always needed to travel outside of the Lehigh Valley for these treatments. (lvhn.org)
  • It is an honor to bring stem cell transplantation and cellular therapies to adults in the Lehigh Valley and its surrounding communities," Dr. Toor says. (lvhn.org)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • Therapeutic Candidate or Device Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells Indication Relapsed and Refractory Multiple Myeloma Therapeutic Mechanism Engineered T cells target and kill BCMA+ Myeloma cells Unmet Medical Need No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. (ca.gov)
  • Several drug therapies are valuable in the treatment of symptomatic MM. Clinicians treat many patients with high-dose therapy and peripheral blood or bone marrow stem cell transplantation. (medscape.com)
Peripheral blood stem1
Risk of multiple myeloma2
  • There is an increased risk of multiple myeloma in certain occupations. (wikipedia.org)
  • 3.5 mg/L, albumin ≥ 3.5 g/dL, normal cytogenetics, no elevated LDH Stage II: Not classified under Stage I or Stage III Stage III: β2M ≥ 5.5 mg/L and either elevated LDH or high-risk cytogenetics [t(4,14), t(14,16), and/or del(17p)] The risk of multiple myeloma can be reduced slightly by maintaining a normal body weight. (wikipedia.org)
Combination with filgrastim1
Active multiple myeloma1
  • The CRAB criteria were formerly the benchmark used to establish presence of active multiple myeloma (as opposed to an earlier, generally asymptomatic, "smoldering" form of the disease). (wikipedia.org)
Plasma cell my1
  • Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. (wikipedia.org)
Engraftment1
  • This ex vivo rabbit-specific oncolytic poxvirus called myxoma virus treatment also effectively inhibits systemic in vivo engraftment of human myeloma cells into immunodeficient mice and results in efficient elimination of primary CD138 + myeloma cells contaminating patient hematopoietic cell products. (elsevierpure.com)
Hematologic malignancies1
  • Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
Mobilize1
  • n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. (duke.edu)
20231
  • Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice. (cancernetwork.com)
Oncology1
  • Participant must have Eastern Cooperative Oncology Group (ECOG) performance status = 1 (participants with ECOG 2 due to pain because of underlying myeloma-associated bone lesions are eligible per investigator's discretion). (who.int)
Filgrastim2
Bone Marrow Tra1
Treatment17
  • It is indicated for the palliative treatment of multiple myeloma. (medscape.com)
  • These mental health issues may be due to living with the illness or health problems that you may get because of myeloma medicines or treatment. (webmd.com)
  • Myeloma and treatment for myeloma can weaken your immunity , making the body prone to many infections. (webmd.com)
  • Objectives To classify subgroups of cancer-related symptoms in patients with multiple myeloma (MM) during treatment and examine between-group differences in demographic and clinical characteristics in addition to functional status. (bmj.com)
  • A latent class analysis was used to categorise cancer-related symptoms in Chinese patients undergoing treatment for multiple myeloma (MM). (bmj.com)
  • Given the strong efficacy data shown in the GENESIS trial, which included patients who are representative of the current multiple myeloma patient population, we believe [motixafortide] will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer," Serlin stated. (cancernetwork.com)
  • Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received. (cancernetwork.com)
  • Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments. (cancernetwork.com)
  • Hear patients with multiple myeloma talk about their treatment journeys. (revlimid.com)
  • Learn more about relapsed multiple myeloma and a treatment option if you relapse on REVLIMID. (revlimid.com)
  • Find multiple myeloma treatment resources available to share and download. (revlimid.com)
  • Multiple myeloma treatment can be complicated. (revlimid.com)
  • We conclude that ex vivo myxoma treatment represents a safe and effective method to selectively eliminate myeloma cells from hematopoietic autografts before reinfusion. (elsevierpure.com)
  • Multiple myeloma--an update on diagnosis and treatment. (qxmd.com)
  • In the past years, new approaches in the diagnosis and treatment were introduced aiming to identify high-risk patients who need proper anti-myeloma treatment. (qxmd.com)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
Relapse1
Survival3
Prognosis1
Solid tumors1
  • The company is advancing a pipeline of investigational medicines for patients with multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors. (biolinerx.com)
Complications2
  • Also, myeloma complications like kidney damage, frequent infections, high blood calcium, and more may change how well your brain works. (webmd.com)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
Diagnosis2
Leukemia2
  • Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia. (nih.gov)
  • Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
HSCT3
Monoclonal6
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • Multiple myeloma may develop from monoclonal gammopathy of undetermined significance (MGUS) that progresses to smoldering myeloma. (wikipedia.org)
  • Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibody proteins - (often using electrophoretic techniques revealing the presence of a monoclonal spike in the results - termed an m-spike), bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. (wikipedia.org)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • Multiple myeloma is a plasma cell (PC) malignancy characterized by the accumulation of monoclonal PCs in the bone marrow and the production of large amounts of a monoclonal immunoglobulin or paraprotein. (qxmd.com)
  • Monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. (medscape.com)
Therapeutic1
  • Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
Transplants1
  • Dr. Toor has more than 20 years of experience with autologous and allogeneic transplants. (lvhn.org)
Maintenance therapy1
  • A 78-year-old woman with lung adenocarcinoma and multiple bone metastases received maintenance therapy with pemetrexed + pembrolizumab for a year. (journaltocs.ac.uk)
Therapy2
Lentiviral vector1
  • The aim of the present study was to assess the effects of sprouty homolog 2 (SPRY2) gene regulation by miR-21 on the occurrence, development and tumor metastasis in multiple myeloma (MM). The miR‑21 expression lentiviral vector (LV)‑anti‑miR‑21 and a liposome transfection method were used to screen MM cell lines with stable silent SPRY2. (spandidos-publications.com)
Bortezomib1
CRAB1
  • Together, these biomarkers and the CRAB criteria are known as myeloma-defining events (MDEs). (wikipedia.org)